Biochemical and Biophysical Research Communications, Vol.529, No.4, 1117-1123, 2020
New synthesized polyoxygenated diarylheptanoids suppress lipopolysaccharide-induced neuroinflammation
In neurodegenerative diseases, such as Alzheimer's disease, Huntington's disease, Parkinson's disease and multiple sclerosis, neuroinflammation induced by the microglial activation plays a crucial role. In effort to develop effective anti-neuroinflammatory compounds, different new linear polyoxygenated diarylheptanoids were synthesized. In LPS-triggered BV-2 microglial cells their ability to reduce the concentration of IL-6 and TNF-alpha pro-inflammatory cytokines was evaluated. Moreover, their effect on NF-kappa B and ATP citrate lyase (ACLY), a recently emerged target of metabolic reprogramming in inflammation, was assessed. Finally, we turned our attention to inflammatory mediators derived from the cleavage of citrate catalyzed by ACLY: prostaglandin E-2, nitric oxide and reactive oxygen species. All compounds showed null or minimal cytotoxicity; most of them had a great anti-neuroinflammatory activity. Diarylheptanoids 6b and 6c, bearing a halide atom and benzyl ether protective groups, exhibited the best effect since they blocked the secretion of all inflammatory mediators analyzed and reduced NF-kB and ACLY protein levels. (c) 2020 Elsevier Inc. All rights reserved.
Keywords:Neuroinflammation;Microglia;Diarylheptanoids;Anti-neuroinflammatory activity;NF-kappa B;ATP citrate lyase